Literature DB >> 7983661

A comparison of 6 months' compliance of patients with rheumatoid arthritis treated with tenoxicam and naproxen. Use of patient computer data to assess response to treatment.

O Nived1, G Sturfelt, S A Eckernäs, P Singer.   

Abstract

OBJECTIVE: To assess longterm compliance in patients with rheumatoid arthritis (RA) of 20 mg tenoxicam or 500-1000 mg naproxen taken daily and to evaluate patient computer data collection.
METHODS: Three hundred and seven patients were treated in a double blind, randomized multicenter study for 6 months. The first 4 weeks of treatment data were collected daily via patient operated computers in parallel with standard assessment at weekly visits to the clinics.
RESULTS: Daily patient data collection was more sensitive than weekly clinical assessments. Six months' compliance was 62% for tenoxicam and 67% for naproxen with comparable rates of withdrawal due to lack of efficacy or adverse drug experiences in both groups. The spectra of adverse drug events found were very similar for both drugs but the rates were higher than in short term studies.
CONCLUSION: Daily computer data collection by patients is superior to classical clinical evaluation in drug studies. The longterm compliance of tenoxicam and naproxen are comparable when treating patients with RA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7983661

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  2 in total

1.  Exploring patient reactions to pen-tablet computers: a report from CaReNet.

Authors:  Deborah S Main; Javan Quintela; Rodrigo Araya-Guerra; Sherry Holcomb; Wilson D Pace
Journal:  Ann Fam Med       Date:  2004 Sep-Oct       Impact factor: 5.166

2.  Does electronic implementation of questionnaires used in asthma alter responses compared to paper implementation?

Authors:  J J Caro; I Caro; J Caro; F Wouters; E F Juniper
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.